{
  "docId": "019de075-e64c-773b-a5bd-08e51f7033a7",
  "docSlug": "8122e3ca3ef658190e4851ff70e19f61",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 25 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 25,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a column-based layout to present key value propositions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e64c-773b-a5bd-08e51f7033a7/4",
  "deckHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7",
  "deckJsonHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7.json",
  "deckAnchorHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80b81a53-e762-4048-8dd3-7ae0b50be827",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.14,
        "x": 0.36,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Portfolio of internally discovered assets with distinct MOAs. RNAi therapeutic PD-L1 inhibitor.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28681d7e-2d7d-4d0f-ab04-e1d0f605413f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.14,
        "x": 0.66,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Strong financial position. Cash runway through Q3 2025.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d2e80ae-fa2a-4d61-a436-b2a18de56142",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.14,
        "x": 0.51,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Lead HBV compound – imdusiran (AB-729) RNAi therapeutic in multiple Phase 2a combination clinical trials. Data shows imdusiran is generally safe and well-tolerated and has shown meaningful suppression of HBsAg while on- or off-treatment.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b17796f-8aa3-47df-be6b-6a9d1af3eaeb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.14,
        "x": 0.81,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Patented LNP technology. Receiving licensing royalties arising from Alnylam’s Onpattro® and seeking damages for Moderna & Pfizer/BioNTech COVID-19 vaccine sales.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "626b41de-e35b-496c-b249-ad78add1cb88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.14,
        "x": 0.21,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Team with virology expertise and proven track record. Discovered, developed & commercialized multiple drugs.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7968d7fe-568c-43df-b2ce-8853b7dee349",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.14,
        "x": 0.06,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Indications with significant unmet medical need & large market opportunities. Focused on developing a functional cure for HBV.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb0f16b2-2b6e-49cc-a29e-0c08bc9227fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.14,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "MOA: Mechanism of Action | PD-L1: Programmed death-ligand 1 | HBsAg: Hepatitis B surface antigen",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eafcf411-05d4-4cee-9220-f460ef965580",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "Investment Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d61dd554-a5a2-4911-b585-ab70064294e2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "8faa7016-90b3-414d-8314-12c8651a9e7c",
      "evidence": "This slide is titled 'Investment Highlights' and contains a summary of key points, making it an executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 3,
      "beatId": "e5f6dd36-1068-4403-8d6c-aaa6a690260f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Our Strategy for Value Creation, Investment Highlights, Pipeline",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 5,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "740fe1b5-bbc6-449b-92b2-3662c17d1011",
      "evidence": "Our Strategy for Value Creation, Investment Highlights, Pipeline",
      "position": 1,
      "objective": "explain the company's strategy and value creation",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}